Lv7
5000 积分 2022-09-16 加入
Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study
1天前
已完结
Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data
1个月前
已完结
Rhabdomyolysis triggered by initiation of tirzepatide
1个月前
已完结
Tirzepatide associated autoimmune encephalitis: A case report
1个月前
已完结
Diabetic lumbosacral radiculoplexus neuropathy after glucagon-like peptide 1 receptor agonist use: A case series
1个月前
已完结
Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?
1个月前
已关闭
Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis
1个月前
已完结
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes(SUSTAIN 3):A 56-Week，Open-Label，Randomized Clinical Trial
2个月前
已完结
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes(SUSTAIN 7):a randomised，open-label，phase 3b trial
2个月前
已完结
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
3个月前
已完结
皖公网安备34019202002308
